Zydus Lifesciences' USA Office Clears USFDA Inspection With Nil Observations
Mumbai: Zydus Lifesciences Limited 's USA office in New Jersey concluded a USFDA inspection of its pharmacovigilance and post-marketing surveillance system with 'nil observations', the company announced on 26 September 2026. Inspection Details The onsite inspection was conducted by the United States Food and Drug Administration (USFDA) from 22 September to 25 September 2026. Zydus Lifesciences…
We haven't written up this one. Free Press Journal has the full story — the link below goes straight to it.
